Event-Driven Stocks

Sagent Pharmaceuticals, Inc.

Healthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕

Signs● 3 good● 1 warningdetails ↓

Financials

SEC XBRL · annual
 FY15FY14FY13FY12FY11FY10
Revenue——————
Operating income−$189,000$6.6M$31.4M−$15.5M−$21.7M−$22.6M
Net income$1.9M$5.1M$29.6M−$16.8M−$26.4M−$24.5M
Total assets$349.7M$380.0M$310.2M$172.3M$230.5M$118.6M
Total liabilities$98.6M$106.2M$74.2M$40.5M$88.8M$57.6M
Equity$251.1M$273.8M$236.0M$131.9M$141.7M−$96.8M
EPS (diluted)$-0.06$0.16$0.99$-0.60$-1.31$-12.53
Shares out.32.1M31.8M28.1M27.9M27.9M2.1M

Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.

Key ratios

from filings · FY2015
Operating margin
—
Net margin
—
Return on equity
0.8%
Return on assets
0.5%
Return on capital (ROCE)
−0.1%
Liabilities / assets
28.2%
Debt / equity
0.39×
Book value / share
$7.83
Revenue growth (YoY)
—
Net income growth (YoY)
−63.0%

Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.

Financial health

forensic scores · FY2015
Altman Z″ (distress)
3.77safe
Accruals / assets
2.7%clean
Piotroski F-Score
2/7weak

Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.

Quality score

EDS Score
47
/ 100
Profitability 67Growth 0Catalyst 33Earnings quality 33Financial strength 100

Our own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.

Signs

● 1 warning● 3 good
  • Negative operating cash flow
  • Conservative leverage (liabilities < 50% of assets)
  • Clean earnings (low accruals)
  • Altman Z″ in the safe zone

Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.

FDA-approved drugs

openFDA · most recent
  • NOREPINEPHRINE BITARTRATE IN 5% DEXTROSEMar 26, 2026
  • CALCIUM GLUCONATE IN SODIUM CHLORIDEDec 30, 2025
  • CALCITONIN-SALMONJul 9, 2025
  • FUROSEMIDEJan 27, 2021
  • GLYCOPYRROLATEFeb 21, 2020
  • PROCHLORPERAZINE EDISYLATEMay 28, 2004
  • VALPROATE SODIUMNov 14, 2002
  • FAMOTIDINE PRESERVATIVE FREEApr 17, 2001

Material events

SEC Form 8-K · most recent

Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.

Recent SEC filings

All filings ↗

Event-driven situations (2)